In EGFR mutation NSCLC, present studies have revealed that EGFR TKIs combined with chemotherapy (28, 29) or antiangiogenic (30) therapy may have better efficacy than monotherapy with EGFR TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.